Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian biotech company Resverlogix Corp has reported favorable results from 28-day toxicology studies conducted on its atherosclerosis drug compound RVX-208.
Subscribe to our email newsletter
The company now intends to focus on an Investigational New Drug (IND) application to support clinical development. “As part of our preparations for human clinical trials, we have characterized important aspects of the efficacy and safety of RVX-208,” said Dr Gregory Wagner, senior vice president of Preclinical Development for Resverlogix.
“The 28-day toxicity studies conducted in rats and monkeys indicate that high doses of RVX-208 are safe and well tolerated on repeated oral administration. These combined findings confirm the positioning of RVX-208 as a novel therapeutic agent designed to positively regulate levels of Apolipoprotein A-1 (ApoA-I) and HDL, along with a significant margin of safety.”